Targeting Solid Tumors With BTK Inhibitors

The repurposing of FDA-approved Bruton’s tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemotherapy-resistant cancer patients. Here we review the emerging evidence regarding the clinical potential of BTK inhibitors in solid tumor therapy. The use...

Descripción completa

Detalles Bibliográficos
Autores principales: Uckun, Fatih M., Venkatachalam, Taracad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079762/
https://www.ncbi.nlm.nih.gov/pubmed/33937249
http://dx.doi.org/10.3389/fcell.2021.650414
_version_ 1783685282145501184
author Uckun, Fatih M.
Venkatachalam, Taracad
author_facet Uckun, Fatih M.
Venkatachalam, Taracad
author_sort Uckun, Fatih M.
collection PubMed
description The repurposing of FDA-approved Bruton’s tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemotherapy-resistant cancer patients. Here we review the emerging evidence regarding the clinical potential of BTK inhibitors in solid tumor therapy. The use of BTK inhibitors may through lead optimization and translational research lead to the development of new and effective combination regimens for metastatic and/or therapy-refractory solid tumor patients.
format Online
Article
Text
id pubmed-8079762
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80797622021-04-29 Targeting Solid Tumors With BTK Inhibitors Uckun, Fatih M. Venkatachalam, Taracad Front Cell Dev Biol Cell and Developmental Biology The repurposing of FDA-approved Bruton’s tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemotherapy-resistant cancer patients. Here we review the emerging evidence regarding the clinical potential of BTK inhibitors in solid tumor therapy. The use of BTK inhibitors may through lead optimization and translational research lead to the development of new and effective combination regimens for metastatic and/or therapy-refractory solid tumor patients. Frontiers Media S.A. 2021-04-14 /pmc/articles/PMC8079762/ /pubmed/33937249 http://dx.doi.org/10.3389/fcell.2021.650414 Text en Copyright © 2021 Uckun and Venkatachalam. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Uckun, Fatih M.
Venkatachalam, Taracad
Targeting Solid Tumors With BTK Inhibitors
title Targeting Solid Tumors With BTK Inhibitors
title_full Targeting Solid Tumors With BTK Inhibitors
title_fullStr Targeting Solid Tumors With BTK Inhibitors
title_full_unstemmed Targeting Solid Tumors With BTK Inhibitors
title_short Targeting Solid Tumors With BTK Inhibitors
title_sort targeting solid tumors with btk inhibitors
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079762/
https://www.ncbi.nlm.nih.gov/pubmed/33937249
http://dx.doi.org/10.3389/fcell.2021.650414
work_keys_str_mv AT uckunfatihm targetingsolidtumorswithbtkinhibitors
AT venkatachalamtaracad targetingsolidtumorswithbtkinhibitors

Ejemplares similares